Genzyme Corp. plans to build a new biomanufacturing plant in Lyon, France, for the production of Thymoglobulin, a treatment used in transplantation, in order to meet the anticipated long-term demand for the drugs current and potential new indications. The company is making additional investments in its global manufacturing infrastructure to support the growth of existing products and future products from its late-stage pipeline. Genzyme is completing the development of a new plant in Belgi...